Division of Biological Chemistry and Biologicals, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Pharm Res. 2022 Jan;39(1):89-103. doi: 10.1007/s11095-021-03158-x. Epub 2021 Dec 27.
Antibody-drug conjugates (ADCs), which are monoclonal antibodies (mAbs) conjugated with highly toxic payloads, achieve high tumor killing efficacy due to the specific delivery of payloads in accordance with mAbs' function. On the other hand, the conjugation of payloads often increases the hydrophobicity of mAbs, resulting in reduced stability and increased aggregation. It is considered that mAb aggregates have potential risk for activating Fcγ receptors (FcγRs) on immune cells, and are internalized into cells via FcγRs. Based on the mechanism of action of ADCs, the internalization of ADCs into target-negative cells may cause the off-target toxicity. However, the impacts of aggregation on the safety of ADCs including off-target cytotoxicity have been unclear. In this study, we investigated the cytotoxicity of ADC aggregates in target-negative cells.
The ADC aggregates were generated by stirring stress or thermal stress. The off-target cytotoxicity of ADC aggregates was evaluated in several target-negative cell lines, and FcγR-activation properties of ADC aggregates were characterized using a reporter cell assay.
Aggregation of ADCs enhanced the off-target cytotoxicity in several target-negative cell lines compared with non-stressed ADCs. Notably, ADC aggregates with FcγR-activation properties showed dramatically enhanced cytotoxicity in FcγR-expressing cells. The FcγR-mediated off-target cytotoxicity of ADC aggregates was reduced by using a FcγR-blocking antibody or Fc-engineering for silencing Fc-mediated effector functions.
These results indicated that FcγRs play an important role for internalization of ADC aggregates into non-target cells, and the aggregation of ADCs increases the potential risk for off-target toxicity.
抗体药物偶联物(ADC)是将高毒性有效载荷与单克隆抗体(mAb)偶联而成的,由于有效载荷根据 mAb 的功能进行特异性传递,因此可实现高肿瘤杀伤功效。另一方面,有效载荷的偶联通常会增加 mAb 的疏水性,从而导致稳定性降低和聚集增加。据认为,mAb 聚集物有可能激活免疫细胞上的 Fcγ 受体(FcγR),并通过 FcγR 内化到细胞中。基于 ADC 的作用机制,ADC 进入靶标阴性细胞可能会引起非靶标毒性。然而,聚集对 ADC 包括非靶标细胞毒性的安全性的影响尚不清楚。在这项研究中,我们研究了靶标阴性细胞中 ADC 聚集物的细胞毒性。
通过搅拌应激或热应激产生 ADC 聚集物。在几种靶标阴性细胞系中评估 ADC 聚集物的非靶标细胞毒性,并使用报告细胞测定法来表征 ADC 聚集物的 FcγR 激活特性。
与未受应激的 ADC 相比,ADC 的聚集增强了几种靶标阴性细胞系中的非靶标细胞毒性。值得注意的是,具有 FcγR 激活特性的 ADC 聚集物在表达 FcγR 的细胞中显示出明显增强的细胞毒性。通过使用 FcγR 阻断抗体或 Fc 工程沉默 Fc 介导的效应子功能,可降低 ADC 聚集物的 FcγR 介导的非靶标细胞毒性。
这些结果表明 FcγR 对于 ADC 聚集物进入非靶细胞的内化起着重要作用,并且 ADC 的聚集增加了非靶毒性的潜在风险。